## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Applica	tion of:	)
O'REILLY	ET AL.	)
Serial No.	To be Assigned	)
Filed:	Currently Herewith	)
For:	ENDOSTATIN PROTEIN AND FRAGMENTS THEREOF	) )



## INFORMATION DISCLOSURE STATEMENT

**Assistant Commissioner for Patents** 

Washington, DC 20231

Sir:

The citation of information on the attached Form PTO-1449, "List of Art Disclosed by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98.

Pursuant to 37 C.F.R. §1.98(d), inasmuch as this application relies on prior application Serial No. 09/154,302 filed September 16, 1998, which in turn relies on prior application Serial No. 08/740,168 filed October 22, 1996, for an earlier filing date under 35 U.S.C. § 120, no copy of any patent, publication or other information previously cited by or submitted to the Office in such prior application is being provided herewith.

Express Mail Label No. EL 329860083 US

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed

to: Assistant Commissioner of Patents, Washington, DC 20231, on September 3. 1999.

Lisa C. Elsevier, Reg. No. P-44,669

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Lisa C. Elsevier

Reg. No. P44,669

JONES & ASKEW, LLP 3424 Peachtree Road, N.E. 2400 Monarch Tower Atlanta, Georgia 30326 (404) 949-2400

EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

AS

AT

**EXAMINER** 

EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted

## LIST OF INFORMATION DISCLOSED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.		SERIAL NO.	FILING DATE	
05212 0640		NOT YET	Currently Herewith	
05213-0640 APPLICANT		AVAILABLE	GROUP	
	. •			
O'REILLY, ET A		DEFEDENCES (Incl.	Juding Author Title Data Partingut Pages Etc.)	
CA			fuding Author, Title, Date, Pertinent Pages, Etc.)	
		Gavrieli, Y. et al., "Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation", J. CellBiol., Vol. 119, pp. 493-501 (1992)		
СВ		Gimbrone, M.A. et al., "Tumor Growth and Neovascularization An Experimental Model using the Rabbit		
		Cornea", J. Natl. Canc. Inst., Vol. 52, No. 2 pp. 413-427 (1974)		
CC		Gimbrone, M.A. et al., "Tumor Dormancy in Vivo by Prevention of Neovascularization", J. of Experi. Med.,		
		Vol. 136, pp. 261-276 (1972)		
CD		Good, D.J. et al., "A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and		
	6624-6628 (		a a fragment of thrombospondin", Proc. Nat. Acad. Sci. USA, Vol. 87, pp.	
CE			nduces blood vessel formation in vivo", Proc. Natl. Acad. Sci. USA, Vol.	
		99, pp. 1937-1941 (1993)		
CF		Grant, D.S. et al., "Two different laminin domains mediate the differentiation of human endothelial cells into		
		capillary-like structures in vitro", Cell, Vol. 58, pp. 933-943 (1989)		
CG		Gross, J.L. et al., "Modulation of Solid Tumor Growth in vivo by bFGF", Proc. Amer. Assoc. Canc. Resh,		
CIT	Vol. 31, p. 7		1.4.1.1.11	
CH		Gross, J.L. et al., "Increased capillary endothelial cell protease activity in response to angiogenic stimuli in		
CI		vitro.", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 80, pp. 2623-2627 (1983)  Gunzler, W.A. et al., "The Primary Structure of High Molecular Mass Urokinase from Human Urine", <i>Hoppe-</i>		
"			63, pp. 1155-1165 (1982)	
CJ		Gupta, S.K. et al., "A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of		
	_	the chemokine platelet factor 4", Proc. Natl. Acad. Sci. USA, Vol. 92, pp. 7779-7803 (1995)		
CK		Holmgren, L. et al., "Dormancy of micrometastases Balanced proliferation and apoptosis in the presence of		
		angiogenesis suppression", Nature Medicine, Vol. 1, No. 2, pp. 149-153 (1995)		
CL		Homandberg, G.A. et al., "Heparin-binding fragments of fibronectin are potent inhibitors of endothelial cell growth", Am. J. Path., Vol. 120, pp. 327-332 (1985)		
СМ			id tumor Growth by Immunoneutralizing Monoclonal Antibody against	
		Human Basic Fibroblast Growth Factor", Canc. Resch., Vol. 51, pp. 6180-6184 (1991)		
. CN		Ingber, D. et al., "Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth",		
		348, pp. 555-557 (199		
co		Johansson, J. et al., "Surfactant Protein B: Disulfide Bridges, Structural Properties, and Kringle Similarities",		
CD		ol. 30, pp. 6917-6921		
CP			on is Associated with a Switch to the Export of bFGF in the Multistep ell, Vol. 66, pp. 1095-1104 (1991)	
cQ			cular endothelial growth factor-induced angiogenesis suppresses tumor	
		vo", Nature, Vol. 362,		
CR	Kivirikko, S	Kivirikko, S. et al., "Primary Structure of the α1 Chain of Human Type XV Collagen and Exon-Intron		
	_	in the 3' Region of th	ne Corresponding Gene", J. Bio. Chem., Vol. 269, No. 7, pp. 4773-4779	
EVANDED	(1994)		DAME CONSIDERED	
EXAMINER	Initial if and an an		DATE CONSIDERED	
EAMMINEK PP.	miniai ii reference	considered, whether or n	not citation is in conformance with MPEP 609; Draw line through citation if not	

in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449, Adapted		Sheet 4 of 6	
rokm P10-1449, Adapted	LIST OF INFORMATION	ON DISCLOSED BY APPLICANT weral sheets if necessary)	
ATTY, DOCKET NO.	SERIAL NO.	FILING DATE	
05213-0640 APPLICANT	NOT YET AVAILABLE	Currently Herewith	
O'REILLY, ET AL		GROOF	
		uding Author, Title, Date, Pertinent Pages, Etc.)	
DA	Knighton, D. et al., "Avascular and Vascular Phases of Tumor Growth in the Chick Embryo", Br. J. Cancer, Vol. 35, pp. 347-356 (1977)		
DB	Lein, W. M. et al., "The blood supply of experimental liver metastases. II. A Microcirculatory study of the normal and tumor vessels of the liver with the use of perfused silicone rubber", <i>Surgery</i> , Vol. 68, No. 2, pp. 334-340 (1970)		
DC	Lerch et al., "Localization of Individual Lysine-Binding Regions in Human Plasminogen and Investigations of Their Complex-Forming Properties", European Journal of Biochemistry, Vol. 107, No. 1, pp. 7-13 (1980)		
DD	Lokker, N.A. et al., "Mutational analysis and molecular modeling of the N-terminal kringle-containing doma of hepatocyte growth gactor identifies amino acid side chains important for interaction with the c-met recepto <i>Prot. Engin.</i> , Vol. 7, pp. 895-903 (1994)		
DE	Maione, T.E. et al., "Inhibition of Angiogenesis by Recombinant Human Platelet Factor-4 and Related Peptiddes", Science, Vol. 247, pp. 77-79 (1990)		
DF	Marti, D. et al., "Expression, purification and characterization of the recombinant kringle 2 and kringle 3 domains of human plasminogen and analysis of their binding affinity for ω-aminocarboxylic acids", Eur. J. Biochem., Vol. 219, pp. 455-462 (1994)		
DG	McLean, J.W. et al., "cDNA sequence of human apolipoprotein(a) is homologous to plasminogen", <i>Nature</i> , Vol. 330, pp. 132-137 (1987)		
DH	Menhart, N. et al., "Construction, Expression, and Purification of Recombinant Kringle 1 of Human Plasminogen and Analysis of Its Interaction with ω-Amino Acids", <i>Biochem.</i> , Vol. 30, pp. 1948-1957 (199).		
DI	Millauer, B. et al., "Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant", <i>Nature</i> , Vol. 367, pp. 576-579 (1994)		
DJ	Moses, M.A. et al., "Identification of an Inhibitor of Neovascularization from Cartilage", <i>Science</i> , Vol. 248 (1990)		
DK	Muragaki, Y. et al., "Mouse col 18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones", <i>Proc. Natl. Acad. Sci.</i> USA, Vol. 92, pp. 8763-8767 (1995)		
DL	Muthukkaruppan, VR., "Angiogenesis in the Mouse Cornea", Science, Vol. 205, pp. 1416-1418 (1979)		
DM	Nelson, J. A. et al., "Murine epidermal growth factor (EGF) fragment (33-42) inhibits both EGF- and laminir dependent endothelial cell motility and angiogenesis", <i>Canc. Resch.</i> , Vol. 55, pp. 3772-3776 (1995)		
DN	Nguyen, M. et al., "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane", <i>Microvascular Research</i> , Vol. 47, pp. 31-49 (1994)		
DO	Nguyen, M. et al., "Elevated Levels of the Angiogenic Peptide Basic Fibroblast Growth Factor in Urine of Bladder Cancer Patients", J. of Nat. Canc. Inst., Vol. 85, No. 3, pp. 241-242 (1993)		
DP	O'Reilly et al., "Endogenous Inhibitors of Angiogenesis", Proc. Am. Assoc. Canc. Resch., Vol. 37, p. 669 (1996)		
DQ	O'Reilly et al., "Angiostatin induces and sustains dormancy of human primary tumors in mice", <i>Nature Medicine</i> , Vol. 2, No. 6, pp. 689-692 (1996)		
DR	O'Reilly et al., "The suppression of Tumor Metastases by a Primary Tumor", Surgical Forum, Vol. XLIV, pp. 474-476 (1993)		
DS	a Lewis Lung Carcinoma", Cell, Vo		
DT	O'Reilly et al., "Angiostatin: A Circulating Endothelial Cell Inhibitor That Suppresses Angiogenesis and Tumor Growth", Cold Spring Harbor Symposia on Quantitative Biology, Vol. LIX, pp. 471-482 (1994)		
DU	a Model for the Study of Endothelia	tory Investigation/A Hemangioendothelioma-Derived Cell Line Its Use as al Cell Biology", <i>Laboratory Investigation</i> , Vol. 63, No. 2, p. 159 (1990)	
DV		ncing of cDNAs for proteins with multiple domains of Gly-Xaa-Yaa collagenous proteins", <i>Proc. Natl. Acad. Sci.</i> USA, Vol. 91, pp. 4229-	
CVAMINED		DATE CONCIDERED	

EXAMINER DATE CONSIDERED

EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

## LIST OF INFORMATION DISCLOSED BY APPLICANT

ATTY. DOCKET NO.	SERIAL NO.	FILING DATE	
05213-0640	NOT YET AVAILABLE	Currently Herewith	
APPLICANT	AVAILABLE	GROUP	
O'REILLY, ET AL			
1-1		luding Author, Title, Date, Pertinent Pages, Etc.)	
EA	Oh, S.P., "Cloning of cDNA and Genomic DNA Encoding Human Type VIII Collagen and Localization of th α1(XVIII) Collagen Gene to Mouse Chromosome 10 and Human Chromosome 21", Genomics, Vol. 19, pp 494-499 (1994)		
EB	Parangi, S. et al, "Antiangiogenic therapy of transgenic mice impairs de novo tumor growth", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 93, pp. 2002-2007 (1996)		
EC	Passaniti, A. et al., "Methods in Laboratory Investigation/A Simple, Quantitative Method for Assessing Angiogenesis and Antiangiogenic Agents Using Reconstituted Basement Membrane, Heparin, and Fibroblast Growth Factor", Lab. Invest., Vol. 67, No. 4, pp. 519-528 (1992)		
ED	Ponting et al., "Plasminogen: a structural review", Blood Coagulation and Fibrinolysis, Vol. 3, pp. 605-614 (1992)		
EE	Powell, J. R. et al., "Amino Acid Sequence Analysis of the Asparagine-288 Region of the Carbohydrate Variants of Human Plasminogen", <i>Biochem</i> , Vol. 22, pp. 923-927 (1983)		
EF	Rastinejad, F. et al., "Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene", Cell, Vol. 56, pp. 345-355 (1989)		
EG	Rehn, M. et al., "α1(XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 4234-4238 (1994)		
ЕН	Rehn, M. et al., "Identification of three N-terminal ends of type XVIII collagen chains and tissue-specific differences in the expression of the corresponding transcripts", J. Biol. Chem., Vol. 270, pp. 5705-4711 (1995)		
EI		-Plasmin Enzyme System", Fibrinolysis, pp. 340-357 (1987)	
ЕЈ	Sage, E.H. et al., "Inhibition of Endothelial Cell Proliferation by SPARC is Mediated through a Ca <sup>2+</sup> -Bindin EF-Hand Sequence", J. Cell. Biochem., Vol. 57, pp. 127-140 (1995)		
EK	Sakamato, N. et al., "Inhibition of angiogenesis and tumor growth by a synthetic laminin peptide, CDPGYIGSR-NH2" Canc. Resch., Vol. 51, pp. 903-906 (1991)		
EL	Sambrook, J. et al., "Expression of Cloned Genes in Escherichia coli", <i>Molecular Cloning Second Edition</i> , Cold Spring Harbor Laboratories Press, pp. 17.37-17.41		
EM	Schaller, J. et al., "Structural Aspects of the Plasminogen of Various Species", <i>Enzyme</i> , 40 pp. 63-69 (1988)		
EN	Shi, G. et al., "Kringle Domains and Plasmin Denaturation", Biochem. Biophy. Resch. Comm., Vol. 178, No. 1, pp. 360-368 (1991)		
ЕО	Sottrup-Jensen, L. et al., "The Primary Structure of Human Plasminogen Isolation of Two Lysine-Binding Fragments and One "Mini-" Plasminogen (MW, 38,000) by Elastase-Catalyzed-Specific Limited Proteolysis", <i>Prog. in Chem. Fibrinolysis and Thrombolysis</i> , Vol. 3, pp. 191-209 (1978)		
EP	Srivastava, A. et al., "The Prognostic Significance of Tumorascularity in Intermediate-Thickness (0.76-4.0mm Thick) Skin Melanoma", Am. J. of Path., Vol. 133, No. 2., pp. 419-424 (1988)		
EQ	Strieter, R.M. et al., "Interferony-inducible protein 10 (IP-10), a member of the C-X-C chemokine family, is an inhibitor of angiogenesis. <i>Biochem. Biophys. Resch. Comm.</i> , Vol. 210, pp. 51-57 (1995)		
ER	Studier, W.F. et al., "Use of T7 RNA polymerase to direct expression of cloned genes", <i>Methods Enzymol.</i> , Vol. 85, pp. 60-89 (1990)		
ES	Teicher, B.A. et al., "Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other antiangiogenic agents", <i>Int. J. Canc.</i> , Vol. 57, pp. 1-6 (1994)		
ET		ed from two separate domains of the matrix protein thrombospondin-1 have	
EU		inhibitor of angiogenesis upon induction of wild type p53 expression in	
EV	Voest, E. E. et al., "Inhibition of Angiogenesis in Vivo by Interleukin 12", J. Natl. Can. Inst., Vol. 87, pp. 581-586 (1995)		
EXAMINER		DATE CONSIDERED	
	itial if reference considered, whether or root considered. Include copy of this form	not citation is in conformance with MPEP 609; Draw line through citation if not with next communication to applicant.	

FORM PTO-1449, Adapted		Sheet 6 of 6
I GAM F10-1449, Auapte	LIST OF INFORMAT	ION DISCLOSED BY APPLICANT everal sheets if necessary)
ATTY. DOCKET NO. 05213-0640	SERIAL NO. NOT YET AVAILABLE	FILING DATE  Currently Herewith
APPLICANT O'REILLY, ET AI		GROUP
17,1		luding Author, Title, Date, Pertinent Pages, Etc.)
FA FA	Walz, D.A. et al., "Amino acid sec Vol. 74, pp. 1969-1973 (1977)	quence of human prothrombin fragments 1 and 2", Proc. Natl. Acad. Sci.,
FB	Weidner, N. et al., "Tumor Angiog Stage Breast Carcinoma", J. Natl.	genesis: A New Significant and Independent Prognostic Indicator in Early- Canc. Inst., Vol. 84, pp. 1875-1887 (1992)
FC	Weidner, N. et al., "Tumor Angiogenesis Correlates with Metastasis in Invasive Prostate Carcinoma", Am Path., Vol. 143, No. 2, pp. 401-409 (1993)	
FD	Weidner, N. et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma", NE J. Med., Vol. 324, No. 1, pp. 1-8 (1991)	
FE	Wiman, B. et al., "On the Specific Interaction Between the Lysine-Binding Sites in Plasmin and Complementary Sites In α <sub>2</sub> -Antiplasmin and Fibrinogen", <i>Biochimica et Biophysica Acta</i> . Vol. 579, pp. 14 154 (1979)	
FF	(MSP, MST1) Confirms MSP as a	quencing, and Expression of Human Macrophage Stimulating Protein Member of the Family of Kringle Proteins and Locates the MSP Gene on humanobiology, pp. 15461-15468 (1993)
FG		
FH	-	
FI		
FJ		
FK		
FL		
FM		
FN		7.446
FO		

EXAMINER pp. Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

EXAMINER